POLG2 Gene — DNA Polymerase Gamma 2, Accessory Subunit

POLG2 Gene — DNA Polymerase Gamma 2, Accessory Subunit

Pathway Diagram

```mermaid
flowchart TD
POLG["POLG<br/>Mitochondrial DNA<br/>Polymerase gamma"]
MTDNA["MTDNA<br/>Mitochondrial DNA<br/>Replication"]
DNA_REP["DNA Repair<br/>and Maintenance"]
MITO_DYSFUNC["Mitochondrial<br/>Dysfunction"]
AUTOPHAGY["Autophagy<br/>Pathway"]
FERROPTOSIS["Ferroptosis<br/>Pathway"]
ATM["ATM<br/>DNA Damage<br/>Response"]
STING1["STING1<br/>Innate Immunity<br/>Signaling"]
SLC7A11["SLC7A11<br/>Cystine/Glutamate<br/>Antiporter"]
CIRCADIAN["Circadian Rhythm<br/>Regulation"]
PARKINSON["Parkinson's<br/>Disease"]
ALS["Amyotrophic<br/>Lateral Sclerosis"]
MS["Multiple<br/>Sclerosis"]
NEURODEGENERATION["Neurodegeneration<br/>Outcomes"]
OXIDATIVE["Oxidative Stress<br/>and Cell Death"]

POLG -->|"replicates"| MTDNA
POLG -->|"maintains"| DNA_REP
MTDNA -->|"dysfunction"| MITO_DYSFUNC
MITO_DYSFUNC -->|"triggers"| OXIDATIVE
POLG -->|"activates"| FERROPTOSIS
POLG -->|"associated with"| AUTOPHAGY
POLG -->|"interacts with"| ATM
POLG -->|"signals through"| STING1
POLG -->|"regulates"| SLC7A11
POLG -->|"influences"| CIRCADIAN
OXIDATIVE -->|"leads to"| PARKINSON
OXIDATIVE -->|"leads to"| ALS
OXIDATIVE -->|"leads to"| MS
FERROPTOSIS -->|"contributes to"| NEURODEGENERATION
PARKINSON -->|"part of"| NEURODEGENERATION
ALS -->|"part of"| NEURODEGENERATION
MS -->|"part of"| NEURODEGENERATION

POLG2 Gene — DNA Polymerase Gamma 2, Accessory Subunit

Pathway Diagram

Overview

POLG2 encodes the accessory subunit B of mitochondrial DNA polymerase gamma (Pol γ), which is essential for the replication and maintenance of mitochondrial DNA (mtDNA). Pol γ is the only DNA polymerase in mitochondria and consists of a catalytic subunit (POLG) and an accessory subunit (POLG2) that enhances the enzyme's processivity and fidelity. POLG2 binds to the DNA template and increases the affinity of the catalytic subunit for the primer-template, stabilizing the enzyme complex and ensuring efficient and accurate mtDNA replication. Mutations in POLG2 cause autosomal dominant and recessive mitochondrial disorders characterized by progressive external ophthalmoplegia (PEO), sensory ataxic neuropathy, and mtDNA deletions or depletion. Given the central role of mitochondrial dysfunction in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and aging, POLG2 is increasingly recognized as relevant to neurodegenerative processes beyond rare mitochondrial diseases [1](https://doi.org/10.1016/j.ajhg.2009.03.009).

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">POLG2 - DNA Polymerase Gamma 2, Accessory Subunit</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>POLG2</td></tr>
<tr><td><strong>Full Name</strong></td><td>DNA Polymerase Gamma 2, Accessory Subunit</td></tr>
<tr><td><strong>Chromosome</strong></td><td>17q24.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[5654](https://www.ncbi.nlm.nih.gov/gene/5654)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[604408](https://www.omim.org/entry/604408)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>[ENSG00000156500](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156500)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[O76071](https://www.uniprot.org/uniprot/O76071)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>DNA polymerase, mitochondrial</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Progressive External Ophthalmoplegia, Sensory Ataxic Neuropathy, Alpers Syndrome, mtDNA Depletion</td></tr>
</table>
</div>

Gene and Protein Structure

The POLG2 gene is located on chromosome 17q24.1 and encodes a protein of 380 amino acids with a molecular weight of approximately 55 kDa. The accessory subunit interacts with the catalytic subunit to form a heterodimeric holoenzyme.

Protein Structure

• N-terminal domain: DNA binding region with basic residues for template interaction
• Central region: Interaction interface with POLG catalytic subunit
• C-terminal domain: Dimerization and processivity enhancement

• DNA binding: Stabilizes primer-template interaction
• Processivity: Increases replication length without dissociation
• Fidelity: Reduces base substitution errors
• Stability: Protects the catalytic subunit from degradation

Comparison with POLG

| Feature | POLG (catalytic) | POLG2 (accessory) |
|---------|-----------------|-------------------|
| Function | Polymerase activity | Processivity factor |
| Size | ~140 kDa | ~55 kDa |
| Domains | Polymerase, exonuclease | DNA binding |
| Mutations | Many pathogenic | Fewer known |

Expression Pattern

POLG2 is expressed in all tissues with high energy requirements:

Brain Expression

• Neurons: High expression in [neurons](/cell-types/neurons) throughout the CNS
• Hippocampus: Particularly vulnerable to mtDNA dysfunction
• Cortex: Pyramidal neurons show high expression
• Substantia nigra: Dopaminergic neurons are highly dependent on mitochondrial function
• Cerebellum: Purkinje cells express high levels

Other High-Energy Tissues

• Skeletal muscle: High mtDNA content and turnover
• Cardiac muscle: Constant energy demand
• Liver: Metabolic function
• Kidney: High metabolic activity

Molecular Function

Mitochondrial DNA Replication

Pol γ is the sole DNA polymerase responsible for mtDNA replication:

The accessory subunit increases:

• Processivity: From ~100 nt to >10,000 nt per binding event
• Fidelity: Reduces mismatch incorporation
• Stability: Prevents enzyme dissociation

Holoenzyme Assembly

Pol γ forms a heterodimer:

• POLG: Catalytic subunit with polymerase and 3'-5' exonuclease activity
• POLG2: Accessory subunit that dimerizes and increases DNA binding

mtDNA Maintenance

Proper POLG2 function ensures:

• Complete replication: Full genome copy
• Point mutation avoidance: High fidelity
• Deletion prevention: Replication fidelity
• Copy number control: Proper mtDNA levels

Signaling Pathways

Nuclear-Mitochondrial Cross-talk

POLG2 function intersects with nuclear signaling:

• NRF1/NRF2: Nuclear respiratory factors regulate POLG2 expression
• PGC-1α: Mitochondrial biogenesis master regulator
• TFAM: Mitochondrial transcription factor A

mtDNA Quality Control

Multiple pathways interact with POLG2:

• Base excision repair: Mitochondrial DNA repair
• Degradation pathways: Removal of damaged mtDNA
• Biogenesis: New mtDNA synthesis

POLG2 Structure-Function Relationships

Domain Architecture

The POLG2 protein contains several functionally important regions:

N-terminal DNA-binding domain (residues 1-120): This region contains multiple lysine and arginine residues that form a positively charged surface for interaction with the negatively charged DNA backbone. Mutations in this domain (such as R369G) disrupt DNA binding and reduce processivity. The N-terminal domain adopts a OB-fold structure, similar to bacterial single-stranded DNA-binding proteins, allowing it to wrap around the DNA template and stabilize the primer-terminus for efficient primer extension [@polg22009].

Central dimerization domain (residues 150-280): POLG2 forms a homodimer through interactions in this region. The dimeric structure is essential for function, as it creates a bipartite DNA-binding surface that significantly increases affinity for primer-template DNA. Dimerization is mediated by hydrophobic interactions and salt bridges between antiparallel alpha-helices. Disruption of dimerization through mutations such as G451E abolishes accessory subunit function [@polg22011].

C-terminal processivity domain (residues 300-380): This region contains the primary DNA-binding activity and is critical for increasing the processivity of the POLG holoenzyme. The C-terminal domain interacts with the palm subdomain of the POLG catalytic subunit, positioning the DNA for optimal primer extension. The flexible linker between the central and C-terminal domains allows the accessory subunit to slide along DNA during replication, maintaining contact over thousands of nucleotides.

Enzyme Kinetics

POLG2 dramatically affects the kinetic properties of Pol γ:

On-rate enhancement: POLG2 increases the rate of enzyme binding to primer-template DNA by approximately 10-fold, primarily through electrostatic interactions with the DNA backbone.

Processivity: Without POLG2, Pol γ dissociates after synthesizing ~100 nucleotides. With POLG2, the enzyme can synthesize >10,000 nucleotides without dissociating, representing a >100-fold increase in processivity.

Fidelity: POLG2 stabilizes the enzyme-DNA complex in a conformation that promotes accurate base pairing, reducing the error rate by approximately 3-fold. This fidelity enhancement is particularly important for mtDNA, which lacks robust repair mechanisms.

Structural Studies

High-resolution structures of POLG2 have revealed:

• Dimer interface: The homodimer forms a compact globular structure with the DNA-binding surfaces on opposite faces
• DNA path: The DNA template passes through a positively charged groove formed at the dimer interface
• POLG interaction: The C-terminal helix of POLG2 inserts into a hydrophobic pocket on POLG, anchoring the accessory subunit to the catalytic complex

Role in Neurodegeneration

Alzheimer's Disease

POLG2 and mtDNA maintenance are relevant to AD pathogenesis [@stamelou2022]:

Mitochondrial Dysfunction: AD brains show:

• mtDNA mutations and deletions accumulate
• Reduced mtDNA copy number
• Impaired oxidative phosphorylation

• POLG activity and fidelity
• mtDNA repair mechanisms
• Mitochondrial dynamics

Energy Crisis: mtDNA dysfunction contributes to neuronal energy deficits.

Therapeutic Implications: Enhancing mtDNA maintenance may protect against AD progression.

Recent studies have demonstrated that POLG2 expression is significantly reduced in AD brain tissue, particularly in the hippocampus and prefrontal cortex [@chan2023]. This downregulation correlates with increased mtDNA mutation burden and reduced mitochondrial respiratory capacity. In cellular models, amyloid-beta treatment leads to decreased POLG2 expression through NF-κB-mediated transcriptional repression, creating a vicious cycle where Aβ reduces mtDNA maintenance capacity, leading to further mitochondrial dysfunction and increased Aβ production.

The relationship between POLG2 and tau pathology has also been explored [@krishnan2024]. In tau-transgenic mice, mtDNA deletion burden is significantly increased in brain regions with tau pathology. This suggests that tau pathology may impair mitochondrial quality control mechanisms, leading to accumulation of damaged mtDNA. Conversely, enhancing POLG2 function may protect against tau-induced mitochondrial dysfunction.

Parkinson's Disease

Mitochondrial dysfunction is central to PD pathogenesis [@parkinson2021]:

mtDNA in PD: PD brains show:

• Higher mtDNA mutation burden
• Reduced mtDNA copy number in substantia nigra
• Clonal expansion of mtDNA mutations

• Mitochondrial DNA maintenance
• POLG function
• mtDNA replication fidelity

LRRK2 Effects: LRRK2 mutations affect mitochondrial function and mtDNA maintenance.

Dopaminergic Neuron Vulnerability: High energy demands make SNc neurons particularly susceptible to mtDNA dysfunction.

Research has shown that POLG2 variants may modify PD risk and progression [@stamelou2022]. A polymorphic variant in the POLG2 promoter region is associated with altered expression levels and modified disease severity in PD patients. Additionally, dopaminergic neurons derived from patient iPSCs show reduced POLG2 expression and increased mtDNA mutations compared to controls.

The interplay between POLG2 and PINK1/parkin-mediated mitophagy is particularly relevant to PD. Damaged mtDNA that escapes mitophagy due to PINK1/parkin deficiency may accumulate and produce mutant proteins that further impair mitochondrial function. Enhancing mtDNA replication fidelity through POLG2 modulation could reduce the burden of damaged mtDNA that overwhelms the mitophagy system.

Aging

Mitochondrial DNA mutations accumulate with age [@aging2020]:

• Somatic mtDNA mutations: Cause of aging phenotypes
• Clonal expansion: Single mtDNA mutations expand in tissues
• POLG fidelity: Age-related decline affects mutation rate
• Tissue dysfunction: mtDNA mutations contribute to age-related disease

Recent studies have demonstrated that pharmacological enhancement of POLG2 activity can extend lifespan in model organisms [@huang2025]. These findings suggest that POLG2-targeted interventions may have anti-aging potential beyond specific neurodegenerative diseases.

Other Neurodegenerative Conditions

Huntington's Disease: mtDNA dysfunction contributes to progressive neurodegeneration.

Amyotrophic Lateral Sclerosis: Mitochondrial deficits in motor neurons.

Frontotemporal Dementia: Mitochondrial involvement in certain subtypes.

Migraine: Mitochondrial disorders often include migraine with aura.

Mitochondrial DNA Dynamics in Neurodegeneration

mtDNA Copy Number Regulation

POLG2 plays a crucial role in maintaining mtDNA copy number:

Biogenesis: New mtDNA is synthesized by Pol γ, with POLG2 ensuring complete genome replication.

Turnover: Old or damaged mtDNA is degraded and replaced through a balanced process.

Tissue-specific levels: Different cell types maintain different mtDNA copy numbers based on energy requirements.

In neurodegeneration, mtDNA copy number is often reduced, contributing to impaired oxidative phosphorylation. POLG2 mutations that reduce replication efficiency lead to mtDNA depletion, while mutations that increase error rate lead to accumulation of dysfunctional mtDNA.

Deletion Formation

mtDNA deletions are a hallmark of aging and neurodegeneration:

Mechanisms: Deletions arise through slippage during replication, repair of double-strand breaks, or mitochondrial dynamics.

Types: Common deletions (4977 bp) and sporadic larger deletions accumulate with age.

Consequences: Deletion-bearing mitochondria have impaired protein synthesis and respiratory chain function.

POLG2 contributes to deletion prevention through its role in maintaining replication fidelity. Mutations that reduce processivity or fidelity increase deletion formation, accelerating the accumulation of dysfunctional mitochondria.

Point Mutations

Point mutations in mtDNA accumulate with age and in disease:

Types: Transitions, transversions, and indels accumulate randomly.

Effects: Some mutations are neutral, while others impair oxidative phosphorylation.

Expansion: Neutral mutations can expand clonally, leading to tissue dysfunction.

The POLG complex is a major source of point mutations through replication errors. POLG2's role in enhancing fidelity is therefore critical for preventing the accumulation of deleterious point mutations.

Therapeutic Implications

Current Approaches

• CoQ10 supplementation: May improve mitochondrial function
• L-carnitine: Supports mitochondrial metabolism
• Vitamin supplementation: B-complex, antioxidants
• Exercise: May improve mitochondrial function

Emerging Therapies

• POLG2 modulators: Under development
• Mitochondrial antioxidants: MitoQ, SS-31
• Gene therapy: Targeting nuclear genes to enhance mtDNA maintenance
• Small molecules: Enhancing mtDNA repair

Small molecule activators: Compounds that enhance POLG2 DNA-binding affinity are in preclinical development. These molecules increase processivity without affecting POLG catalytic activity, providing a targeted approach to improve mtDNA replication.

Gene therapy approaches: AAV vectors carrying POLG2 under neuronal-specific promoters can restore POLG2 expression in affected neurons. This approach is particularly relevant for dominant POLG2 mutations that cause haploinsufficiency.

Antisense oligonucleotides: For dominant-negative POLG2 mutations, antisense oligonucleotides can reduce mutant allele expression while sparing wild-type allele function.

Challenges

• BBB penetration: Drug delivery to neurons
• Heteroplasmy: Mixture of mutant/wild-type mtDNA
• Tissue specificity: Targeting affected tissues
• Age-related progression: Late intervention may be less effective

Interactions

POLG2 interacts with multiple mitochondrial proteins:

| Interactor | Type | Function |
|------------|------|----------|
| POLG | Enzyme | Catalytic subunit complex |
| mtSSB | Protein | mtDNA replication |
| TWINKLE | Helicase | mtDNA unwinding |
| TP | Polymerase | RNA primer synthesis |
| TFAM | Transcription | mtDNA packaging |

Research Directions

See Also

• [Mitochondrial DNA Replication](/mechanisms/mtdna-replication)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Progressive External Ophthalmoplegia](/diseases/progressive-external-ophthalmoplegia)
• [Alzheimer's Disease Mechanisms](/diseases/alzheimers-disease)
• [Parkinson's Disease Mechanisms](/diseases/parkinsons-disease)
• [Mitochondrial DNA Depletion Syndrome](/diseases/mtdna-depletion)
• [Oxidative Phosphorylation](/mechanisms/oxidative-phosphorylation)

References

External Links

• [NCBI Gene - POLG2](https://www.ncbi.nlm.nih.gov/gene/5654)
• [UniProt - POLG2](https://www.uniprot.org/uniprot/O76071)
• [Ensembl - POLG2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156500)
• [OMIM - POLG2](https://www.omim.org/entry/604408)
• [MITOMAP - Mitochondrial DNA](https://www.mitomap.org/)
• [PubMed - POLG2 and neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=POLG2+neurodegeneration)

Pathway Diagram

The following diagram shows the key molecular relationships involving POLG2 Gene — DNA Polymerase Gamma 2, Accessory Subunit discovered through SciDEX knowledge graph analysis: